GSK shutting down Biopolis neural unit

Singapore

IN a move to cut costs, United Kingdom pharma giant GlaxoSmithKline (GSK) will begin a phased closure of its operations at its neural pathways discovery performance unit at Biopolis, following its global review to refocus the global pharmaceuticals business.

While it declined to reveal the number of employees affected by the closure, the drugmaker, which employs 1,700 people here, said it remains committed to research and development (R&D) in Singapore, which is a "a key location for GSK's global manufacturing and commercial operations".